+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neoglycoproteins as carriers for receptor-mediated drug targeting in the treatment of experimental visceral leishmaniasis



Neoglycoproteins as carriers for receptor-mediated drug targeting in the treatment of experimental visceral leishmaniasis



Journal of Protozoology 37(5): 358-364



Methotrexate (MTX) coupled to mannosyl bovine serum albumin (BSA) was taken up efficiently through the mannosyl receptors present on macrophages. Binding experiments indicate that conjugation does not decrease the affinity of the neoglycoprotein for its cell surface receptor. The drug conjugate eliminated intracellular amastigotes of Leishmania donovani in mouse peritoneal macrophages about 100 times more efficiently than free drug on the basis of 50% inhibitory dose. Inhibitory effect of the conjugate was directly proportional to the density of sugar on the neoglycoprotein carrier. Colchicine and monensin, inhibitors of receptor-mediated endocytosis, can prevent the leishmanicidal effect of the conjugate. Antileishmanial effect of the conjugate can be competitively inhibited by mannose-BSA and mannan. In a murine model of experimental visceral leishmaniasis the drug conjugate reduced the spleen parasite burden by more than 85% in a 30-day model whereas the same concentration of free drug caused little effect. These results indicate that MTX-neoglycoprotein conjugate binds specifically to macrophages, and is internalized and degraded in lysosomes releasing the active drug to act on Leishmania parasites. These results also represent the potential for a general approach to intracellular targeting of clinical agents for macrophage-associated disorders.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040780180

Download citation: RISBibTeXText

PMID: 2213650

DOI: 10.1111/j.1550-7408.1990.tb01158.x


Related references

Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis. Journal of Microencapsulation 28(4): 301-310, 2011

Sugar receptor mediated drug delivery to macrophages in the therapy of experimental visceral leishmaniasis. Biochemical & Biophysical Research Communications 166(1): 404-410, 1990

Importance of drug carriers in the treatment of visceral leishmaniasis. Medecine Tropicale 55(1): 73-78, 1995

Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. Journal of Infectious Diseases 189(6): 1024-1034, 2004

Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients. Journal of Antimicrobial ChemoTherapy 68(9): 2059-2065, 2013

Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. Journal of Drug Targeting 19(4): 239-250, 2011

Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting. Acs Nano 7(12): 10597-10611, 2013

Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis. Iranian Journal of Pharmaceutical Research 13(4): 1357-1367, 2014

Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Tropica 93(3): 295-301, 2005

Cisplatin along with herbal drug treatment reduces the percentage of regulatory T cells and decreased the severity of experimental visceral leishmaniasis. Journal of Microbiology Immunology and Infection 51(4): 435-445, 2018

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. Plos Neglected Tropical Diseases 6(5): E1657, 2012

New therapy for visceral leishmaniasis. India licenses miltefosine, the first oral drug for visceral leishmaniasis. Weekly Epidemiological Record 77(25): 210-212, 2002

Epidemiological studies on american visceral leishmaniasis in ceara state brazil xiv. experimental visceral leishmaniasis in dogs preliminary results. Memorias do Instituto Oswaldo Cruz 81(Suppl.): 64, 1986

Photosensitizer-mediated mitochondria-targeting nanosized drug carriers: Subcellular targeting, therapeutic, and imaging potentials. International Journal of Pharmaceutics 520(1-2): 195-206, 2017

Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. European Journal of Immunology 33(6): 1508-1518, 2003